Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$892 Mln
P/E Ratio
--
P/B Ratio
3.23
Industry P/E
--
Debt to Equity
0.01
ROE
-0.66 %
ROCE
-56.55 %
Div. Yield
0 %
Book Value
0.43
EPS
-0.27
CFO
$-575.30 Mln
EBITDA
$-710.51 Mln
Net Profit
$-705.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Geron (GERN)
| -61.02 | -16.36 | -54.00 | -63.59 | -2.30 | 3.71 | -9.89 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Geron (GERN)
| 67.07 | -12.81 | 98.36 | -23.27 | 16.91 | 36.00 | -44.27 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk... myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. Address: 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404 Read more
Chairman of the Board, President & CEO
Dr. John A. Scarlett M.D.
Chairman of the Board, President & CEO
Dr. John A. Scarlett M.D.
Headquarters
Foster City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Geron Corporation (GERN) stood at $ 594 Mln as on 31-Dec-24
The share price of Geron Corporation (GERN) is $1.38 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Geron Corporation (GERN) has given a return of -2.3% in the last 3 years.
Geron Corporation (GERN) has a market capitalisation of $ 892 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Geron Corporation (GERN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Geron Corporation (GERN) and enter the required number of quantities and click on buy to purchase the shares of Geron Corporation (GERN).
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. Address: 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404
The CEO & director of Dr. John A. Scarlett M.D.. is Geron Corporation (GERN), and CFO & Sr. VP is Dr. John A. Scarlett M.D..
There is no promoter pledging in Geron Corporation (GERN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Geron Corporation (GERN) | Ratios |
|---|---|
|
Return on equity(%)
|
-66.09
|
|
Operating margin(%)
|
-202.7
|
|
Net Margin(%)
|
-226.73
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Geron Corporation (GERN) was $0 Mln.
$-0.02
(
